{
    "clinical_study": {
        "@rank": "119168", 
        "arm_group": [
            {
                "arm_group_label": "RX-10045 active arm", 
                "arm_group_type": "Experimental", 
                "description": "RX-10045 Opththalmic Solution, 0.09%"
            }, 
            {
                "arm_group_label": "Vehicle for RX-10045 arm", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Vehicle of RX-10045 Ophthalmic Solution"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary purpose of this study is to assess the efficacy, tolerability and safety of\n      RX-10045 Ophthalmic Solution in patients with Dry Eye Disease."
        }, 
        "brief_title": "A Study of RX-10045 in the Treatment of Dry Eye Disease", 
        "completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "condition": "Dry Eye Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Dry Eye Syndromes", 
                "Keratoconjunctivitis Sicca", 
                "Eye Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Have a patient reported history of dry eye in both eyes\n\n          2. Presence of dry eye symptoms\n\n          3. Presence of dry eye signs, destabilized tear film break-up time and corneal staining\n\n        Exclusion Criteria:\n\n          1. Known contraindications or sensitivities to study medication or its components\n\n          2. Any ocular condition that, in the opinion of the investigator, could affect the\n             subject's safety or trial parameters\n\n          3. Use of disallowed medication during the period indicated prior to the enrollment or\n             during the study\n\n          4. Be a female who is currently pregnant, planning a pregnancy, lactating, or not using\n             a medically acceptable form of birth control"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01675570", 
            "org_study_id": "CTD1201"
        }, 
        "intervention": [
            {
                "arm_group_label": "RX-10045 active arm", 
                "description": "One drop of RX-10045 ophthalmic solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.", 
                "intervention_name": "RX-10045", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vehicle for RX-10045 arm", 
                "description": "One drop of RX-10045 placebo solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.", 
                "intervention_name": "Vehicle for RX-10045", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "RX-10045", 
            "Dry Eye Disease"
        ], 
        "lastchanged_date": "February 7, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Andover", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "01810"
                }, 
                "name": "Andover Eye Associates"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase II, Multi-Center, Randomized, Placebo-Controlled, Double-Masked Study of RX-10045 (0.09%) in the Treatment of Dry Eye Disease", 
        "overall_official": {
            "affiliation": "Andover Eye Associates", 
            "last_name": "Gail Torkildsen, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Corneal staining", 
                "safety_issue": "No", 
                "time_frame": "Baseline to day 28"
            }, 
            {
                "measure": "Worst symptom score", 
                "safety_issue": "No", 
                "time_frame": "Baseline to day 28"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01675570"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Ocular discomfort symptom score", 
                "safety_issue": "No", 
                "time_frame": "Baseline to day 28"
            }, 
            {
                "measure": "Tear film break-up time", 
                "safety_issue": "No", 
                "time_frame": "Baseline to day 28"
            }, 
            {
                "measure": "Visual-related function subscale of Ocular Surface Disease Index score", 
                "safety_issue": "No", 
                "time_frame": "Baseline to day 28"
            }
        ], 
        "source": "C.T. Development America, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "C.T. Development America, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}